To investigate the pathology of excised testicular lesions <10 mm in size.
Patients and Methods
The pathological reports of 2 681 patients with testicular lesions from Barts Health NHS Trust and Oxford University Hospitals NHS Foundation Trust were reviewed as part of a service evaluation audit from January 2003 to May 2016. Cases in which the lesion had a maximum diameter of <10 mm were selected. Clinical features were also accessed, where available, to examine patient demographics, prediagnostic levels of serum markers, ultrasonographic findings and clinical details.
Results
A total of 81 patients with a lesion size <10 mm on histology were identified and, of these, 16 (20%) had a lesion diameter <5 mm. Of the 81 patients, 56 (69%) had benign lesions. Of 16 patients with a benign lesion <5 mm in diameter, 15 underwent orchidectomy and just one underwent partial orchidectomy. Preoperative tumour markers were available in 47/81 patients. None of the 16 malignant tumours in these 47 patients were associated with raised tumour markers, while seven of 31 remaining patients with benign lesions had raised a-fetoprotein and lactate dehydrogenase levels. In total there were 25/81 malignant cases (31%), which were all germ cell tumours (GCTs): 15 seminomas (60%) and 10 nonseminomatous GCTs (40%). Only one GCT had a diameter of <5 mm, and this was a regressed tumour within an 18-mm area of granulomatous inflammation. Only one GCT relapsed: a clinical stage I, embryonal carcinoma of 6 mm in maximum diameter. The 56 'benign' cases included 34 sex cord stromal tumours, including 23 Leydig cell tumours (41%), eight Sertoli cell tumours (14%) and three mixed sex cord stromal tumours (5%). None showed any malignant features. The remaining 22/56 lesions (40%) were lesions with no further follow-up. Benign lesions seemed to be associated with a small diameter, and we found <5 mm to be the best threshold for predicting benign vs malignant lesions (P = 0.002).
Conclusion
The majority of testicular lesions <10 mm, identified by radiology, were benign, although approxmiately one-third were malignant. In the present study, 100% of lesions <5 mm in diameter were benign. Tumour markers appear to be unhelpful in the distinction of these small tumours. We suggest that regular ultrasound surveillance be more widely used for testicular lesions of this size. Testicular tumours now have a very high cure rate and changes in size of lesions may be monitored prospectively with minimal risk of increased morbidity. Patients who undergo an orchidectomy for lesions <5 mm are 'victims of modern imaging technology'. If
Introduction
The prevalent use of trans-scrotal ultrasonography to image the testis has led to the detection of an increasing number of impalpable testicular lesions, often <10 mm in maximum diameter [1, 2] . The accuracy and the sensitivity of ultrasonography have the ability to distinguish testicular lesions from paratesticular lesions [3] , but do not allow specific differentiation between benign and malignant lesions [4, 5] . The finding of a small impalpable testicular lesion <10 and <5 mm creates debate between pathologists and urologists, especially when clinical findings, such as serum markers a-fetoprotein (AFP), b-human chorionic gonadotropin (b-hCG) and lactate dehydrogenase (LDH), are within normal limits and ultrasonographic findings are ambiguous. This clinical/radiological uncertainty may lead to surgery in the form of either partial or, more frequently, total/radical orchidectomy. While testicular malignancies may have serious clinical consequences, they remain highly treatable and specific. Moreover, clinical guidelines are available for the diagnosis, staging and treatment of testicular cancer which can help, together with clinician expertise, to decide the best options for the patient.
No specific national or international guidelines are currently available to help to manage small testicular lesions <10 mm. The National Comprehensive Cancer Network suggests considering inguinal biopsy if an ambiguous intratesticular mass is identified on US on ultrasound (US) [6] .
The European Association of Urology does not address the issue of tumour size, but suggests in equivocal cases "a testicular biopsy (and enucleation of the intraparenchymal tumour) is taken for frozen (fresh tissue) section histological examination" [7] .
The acronym 'VOMIT' (victims of modern imaging technology) [8] has been applied previously to patients who are treated unnecessarily for radiologically suspicious findings. Although emotive, it highlights the dangers of overdiagnosis in 21st century medicine. Patients who undergo surgery for lesions <5 mm are victims of overtreatment and psychological stress that could be avoided. We define those patients as victims of modern imaging technology because the small lesions were removed unnecessarily, leading patients to undergo superfluous plastic surgery.
The aim of the present study, therefore, was to investigate the pathology of excised 'small' suspicious testicular lesions, identified by ultrasonography in two major tertiary referral practices, based on the hypothesis that the vast majority of such small tumours would be of no clinical consequence and could be managed with repeated imaging without surgical intervention, and to determine the optimum size to use as a threshold for the decision to advise surgery.
Materials and Methods
Barts Health NHS Trust and the Oxford University Hospitals NHS Foundation Trust (OUHFT) pathology databases were searched, for the period January 2003 to May 2016, as a service evaluation audit of small testicular masses. Anonymous reports were collected from all patients treated at Barts Health NHS Trust and OUHFT supra-regional testicular cancer centre and from external consultation cases. For the data retrieval, Systematized Nomenclature of Medicine Clinical Terms and various text search terms were used to obtain data on the anatomical sites, surgical procedures and final histological diagnosis. Tumour size was defined as the maximum diameter, as measured by the pathologist either macroscopically or microscopically; in most cases, this had been determined macroscopically, with occasional reports revising the size on microscopic examination (usually in the case of small lesions). Selected cases underwent slide review (C.V./D.M.B.) where the size of the lesion was unclear from the report.
Pathological reports of small testicular masses were selected if the macroscopic or microscopic maximum diameter of the lesion was <10 mm and only if the patient underwent orchidectomy or partial orchidectomy. Biopsies and postchemotherapy surgeries were therefore excluded. Patient demographic information, prediagnostic levels of serum markers, including AFP, b-hCG and LDH, ultrasonography reports, follow-ups and clinical records were accessed where available, including symptoms at presentation (such as cryptorchidism, palpable lump, testicular pain or swelling, and infertility). Referral hospitals were contacted when no information was available in our systems.
Statistical Analysis
All statistical analyses were completed using SPSS version 24 software (SPSS Inc, IBM Corp.). A chi-squared test was used to assess categorical variables, to compare the mean age of patients with benign and malignant lesions. Fisher's exact test of independence was used to determine the optimum threshold below which the number of benign lesions would be highest. All tests were two-sided and P values < 0.05 were taken to indicate statistical significance.
Ethical approval was obtained by Local Ethics Committee (REC No: 09/H0704/4+5) for the use of anonymized data from Barts Health NHS Trust. The OUHFT used the Thames Valley testicular cancer supra-regional database, which is approved by the Trust Caldicott Guardian and is registered on the Information Asset Register.
Results
The pathological reports of 2 681 patients from Barts Health NHS Trust (1 481 cases) and OUHFT (1 200 cases) were reviewed.
Of 2 681 cases, 81 (3%) were identified with a lesion size <10 mm in maximum diameter (range 1.7-9.6 mm). Of these 81 cases, 25 (31%) were germ cell tumours (GCTs) and 56 (69%) were benign lesions. Sixteen (20%) had a diameter <5 mm and were benign. Only one GCT had a diameter of <5 mm and, when reviewed, this was a partially regressed tumour within an 18-mm area of granulomatous 576 © 2017 The Authors BJU International © 2017 BJU International inflammation which would have appeared larger on ultrasonography. One GCT identified as an embryonal carcinoma of 6 mm in maximum diameter and presenting initially as clinical stage I, relapsed.
The overall mean age of the 81 cases was 40 years (range 4 months to 88 years), the median (interquartile range [IQR]) age was 35 (28-49.5) years. For patients with benign lesions, the mean age was 43.6 years, and the median (IQR) was 41 (29-55) years. The mean age for patients with a malignant lesion was 32.6 years and the median (IQR) was 31 (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) years.
Comparison of the mean age of patients with malignant and benign lesions using the chi-squared test showed that those with a malignant diagnosis were significantly younger (P = 0.005). Comparison of the age of patients with lesions <5 mm vs those with lesions 5-9 mm showed no significant difference (P = 0.374).
A total of 77 of the 81 patients (95%) underwent orchidectomy, including 15 with lesions <5 mm; four of the 81 patients (5%) underwent partial orchidectomy and just one of them had a tumour size <5 mm. Characteristics of the 81 cases are available in Table 1 . and haemangioma, n = 1 [AFP: 6 U/mL, b-hCG: <1 U/L]) and three patients presented with raised LDH levels (epidermoid cyst, n = 1; epididymal cyst, n = 1; Leydig cell hyperplasia, n = 1). Characteristics of the 16 patients with a lesion <5 mm in diameter are shown in Table 2 .
As a retrospective study from two supraregional databases, most of the ultrasonographical/radiological reports were not available in our system. Ultrasonography was performed locally prior to orchidectomy and is difficult to analyse in a retrospective manner; however, Figs 1 and 2 show selected ultrasound images of cases from Barts Health NHS Trust.
The final histology of the 81 cases showed: 15 (19%) classic seminomas; 10 (12%) non-seminomatous GCTs; seven mixed GCTs with an embryonal carcinoma percentage of 30-98% and three pure embryonal carcinomas (Table 3) ; 23 (28%) Leydig cell tumours; eight (10%) Sertoli cell tumours; three (4%) sex cord stromal tumours; 22 (27%) benign forms (one Sertoli cell nodule, two Leydig cell hyperplasias, two tunica albuginea cysts, two haemangiomas, one necrotic nodule, two epidermoid cysts, two epididymal cysts, three pseudotumours, one ectopic nodule of adrenal cortex, one non-specific chronic inflammation, one cystic transformation of rete testis, two adenomatoid tumours and two fibromas of the tunica albuginea). The epidermoid cysts seen within the testis are now classified as prepubertal type teratomas, but are nevertheless still benign in behaviour.
None of the sex cord stromal tumour cases showed any malignant features, such as lymphovascular invasion, invasion of other structures, necrosis and increased mitotic activity. By definition, they were all of low risk on size grounds.
Fisher's test was carried out to determine the optimum threshold to predict benign vs malignant lesions. Benign lesions were associated with a small diameter and <5 mm was defined as best threshold to predict benign vs malignant lesions (P = 0.002).
Discussion
Three percent of testicular neoplasms reviewed in our centres were a maximum of <10 mm in diameter. Most of these lesions were benign at final diagnosis, while the incidence of malignant lesions <10 mm in diameter was low. The present study supports and confirms results of previous studies suggesting that testicular lesions <10 mm in maximum diameter are mostly benign . We also have found that orchidectomy has been overused and, in some cases, has even been unnecessary as a consequence of the combination of misleading tumour markers and equivocal radiology results. We suggest an optimum threshold of <5 mm, below which the number of benign pathologies will be higher and malignancy extremely unlikely. The introduction of and improvements in ultrasonography have led to an increase in the detection of small testicular lesions. A summary of the results from studies reporting benign and malignant testicular lesions <10 mm in diameter is shown in Table 4 .
Although small testicular lesions are frequently benign, malignant lesions <5 mm have been reported in the literature. Muller et al. [29] reported testicular lesions ≤5 mm in diameter and described their management. They found 20 incidental lesions ≤5 mm, after urological and 
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© 2017 The Authors BJU International © 2017 BJU International sonographic examination. While 16 cases had a benign histology after frozen-section examination, the remaining four were identified as seminomas at final diagnosis (diameter of the lesions ranging from 2 to 4 mm) and the patients underwent orchidectomy. Fabiani et al. [18] reported a series of 15 patients who underwent a diagnostic testicular biopsy for suspected testicular nodules. They found 10 lesions <10 mm and three lesions <5 mm in size, two of which were identified as seminomas and one as a Leydig cell tumour. Colpi et al. [14] reported a series of six patients, five of whom were found to have an impalpable testicular lesion on ultrasonography conducted for infertility, and one of whom had a palpable mass. Tumour marker levels were normal in all of them. The patients underwent frozensection analysis. Final diagnosis showed four benign lesions with diameters ranging from 4 to 6 mm and one lesion, identified as a seminoma, of 3 mm in maximum diameter.
Avci et al. [11] reported 11 patients with non-palpable lesions identified after ultrasonographic examination conducted for reasons such as routine military control, infertility and orchialgia. Tumour makers were all within normal limits in these patients. The diameter lesion range was 4-9 mm. Frozen-section analysis was first performed, then the patients underwent radical orchidectomy, which showed five GCTs at final diagnosis (one of them 4 mm in maximum diameter) and four benign lesions (diameter range 4-7 mm).
There is uncertainty in the literature with regard to the optimum treatment for these lesions. The lack of guidelines or thresholds available to distinguish malignant lesions from benign lesions, especially when found to be <10 and <5 mm, combined with the ambiguity and the incapacity of ultrasonography and tumour markers to distinguish between GCT, germ cell tumour. 7 2.5-16 Not specified Not specified Not specified Not specified Shilo et al. (2012) [24] 131 5-150 0 Not specified Not specified 4 (<10) Tal et al. (2004) [25] 11 6-38 0 Not specified 0 Not specified Toren et al. (2010) [26] 46 1-10 Not specified Not specified Not specified Not specified Ye et al. (1999) [27] 14 5-30 0 6 (not specified) Unknown 8 (not specified)
© 2017 The Authors BJU International © 2017 BJU International 579 them, has led to an overuse of radical orchidectomy, although partial orchidectomy may be used for selected cases. We recognise that the size detected ultrasonographically may differ somewhat from that seen either macroscopically or microscopically by the pathologist. In general, formalin fixation may lead to shrinkage of the tumour. A difference of 1-2 mm can also occur because of the resolution of the probes used in ultrasonography and operator variability. The very high frequency probes at 16 MHz provide higher resolution and therefore more accuracy for size; a frequency of 9 MHz will have greater variance. This implies that both 5-and 10-mm thresholds will be an even more conservative method if used ultrasonographically. Moreover, while raised tumour markers are of use in evaluation of the patients, we know that marginally raised tumour markers can be noncancer-related: cannabis use may cause a rise in b-hCG levels, and liver disease leads to rises in AFP levels. LDH elevations can have multiple causes, such kidney disease, heart attack or muscle injuries.
Alternative approaches are already used in urology to avoid an immediate radical orchidectomy, such as partial orchidectomy, frozen-section examination and radiological surveillance. Partial orchidectomy can preserve the testis parenchyma, with associated psychological and cosmetic benefits, avoiding the unnecessary and potential loss of infertility or hormone deficiency.
Frozen-section examination is an alternative to surveillance or orchidectomy. While for some authors it is considered a reliable procedure, able to distinguish between benign and malignant lesions [30] , for others frozen-section examination has led to inconclusive results: three studies have shown false-negative frozen sections results [11, 22, 31] . While possible in high-volume centres with considerable expertise, we do not believe that frozen-section evaluation for small impalpable and often challenging lesions is a helpful way to avoid unnecessary orchidectomy in routine urology practice.
The third available option to avoid radical orchidectomy is radiological surveillance. Toren et al. [26] investigated patients for infertility and 46 of them were found to have a small testicular mass, with the masses having a mean (range) size of 4 (1-10) mm. Radiological surveillance was offered to the patients. In total, 38 patients were followed up by serial ultrasonography and eight underwent surgery (one radical orchidectomy and seven partial orchidectomies). Of these latter eight patients, two had a growing mass but just one at the final diagnosis had a pure seminoma (increasing in size from 3 to 6 mm at 3-month follow-up); in the other six, the surgery was by patient choice and all the seven masses were benign. Eifler et al. [17] studied a series of 49 patients presenting with infertility who were found to have an abnormality on scrotal ultrasonography. All the lesions were followed by ultrasonography and were biopsied or excised. Eleven out of 49 of them had a lesion <5 mm and all were benign. The patients who had lesions <5 mm in size, negative markers and no internal echo were followed by active transscrotal surveillance, with repeated sonography after 3-6 months. If there was no interval growth, the patient underwent biopsy during the testicular sperm extraction.
Connolly et al. [16] identified 12 patients with incidental and impalpable tumours <10 mm in maximum diameter and they were managed by ultrasonographic surveillance. Their mean (range) age was 54 (34-76) years and the mean (range) lesion size was 4.9 (1.5-9.8) mm. In 11 patients there were no changes in size during follow-up. One patient showed a lesion growth after 4-month follow-up, which was diagnosed as a seminoma of 10 mm in maximum diameter, after orchidectomy.
Although, in other studies, the threshold used to distinguish malignant from benign lesions ranged from <2.5 to <1.5 cm [10, 20, 32] , in our cohort all the lesions <5 mm in size (20%) showed benign histology and no malignant lesions have been found with this diameter size.
We suggest that testicular lesions <10 mm, and in particular those <5 mm in size, could be easily monitored by radiological surveillance as the cure rate for clinically localized GCTs is close to 99%. We would define patients who underwent surgery for a lesion <5 mm as victims of modern imaging technology because the small lesions were removed unnecessarily. Considering also that any malignant testicular tumour grows initially from a small nodule [18] , and that the doubling time for a GCT is 10-30 days [33] , changes in size of lesions and vascularity could be checked prospectively with minimal risk of increased morbidity, and, if any changes have occurred, the patient could proceed to either partial or total orchidectomy. Previous studies suggested that, for patients with negative tumour markers, a finding of a nodule <5 mm (with no rete involvement and a mass occupying <30% of the testes) and colour Doppler ultrasonography findings compatible with a benign lesion, trans-scrotal ultrasonography would be recommended every 3 months for 12 months [2] and then annually for 3 years [34] , both to check for any changes and to avoid any stress and anxiety for the patient or a testis-sparing surgery using an inguinal approach, depending on the patient choice.
Our suggested management of testicular lesions <10 mm is shown in a flow chart (Fig. 3) and we would recommend the discussion of ambiguous cases at the multidisciplinary team meeting.
Limitations of the present study include its retrospective nature and limited access to clinical and radiological information when the initial surgery occurred at multiple institutions. This information should form an important part of any prospective surveillance study.
In conclusion, men with lesions <5 mm in diameter, negative tumour markers and no relevant risk factors should not undergo early orchidectomy. Those undergoing surgery for a lesion 5-10 mm in diameter should be counselled that twothirds of lesions in this category are benign. We wish to use this threshold in a future prospective trial aimed at avoiding unnecessary surgery in the 'worried well'.
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